Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Slides:



Advertisements
Similar presentations
Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.
Advertisements

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.
New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Measuring the latent HIV Reservoir
Short video on patients’ perspectives on cure
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
F3 Microbes and biotechnology
CCR5 : and HIV Immunity Gene Variation Works for and Against HIV Ashley Alexis & Hilda Hernandez.
Virologic and immunologic response following antiretroviral therapy initiation among pregnant and postpartum women with acute HIV-1 infection: MOPDB0101.
In vivo analysis of HIV replication and persistence in the myeloid compartment J. Honeycutt, A. Wahl, J. Foster, R.A. Spagnulo and J. Victor Garcia Division.
HIV RESISTANCE AND TREATMENT FAILURE Dr. Jeremy Nel Department of Infectious Diseases Helen Joseph Hospital May 2015.
EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.
2014 “Towards an HIV Cure” symposium Melbourne A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-nai ̈ ve individuals.
Current HIV basic science research topics. Toddler "Functionally Cured" of HIV Infection- “the Mississippi Baby” First well-documented case of an HIV.
Measuring the latent HIV Reservoir
Strategies for Targeting and Eradicating the HIV Reservoir
Hematopoietic stem cell based gene therapy for HIV diseases
David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Viruses.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.
HIV, CD4, and More Karen Hutcherson Jenn Mann Elizabeth McCauley Michael Powers Courtney Wilson.
Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution.
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.
Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.
The Berlin Patient and CCR5. Tim Brown: the only man to have been cured of HIV  Brown was diagnosed with HIV in 1995  11 years on antiretroviral therapy.
Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated.
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Non-Infectious Papilloma virus–like Particles (VLPs) inhibit HIV-1 replication: Implications for immune control of HIV-1 replication by IL-27. Laboratory.
HIV-1 infected subjects treated with an autologous dendritic cell therapy (AGS-004), exhibited a significant reduction in viral load (when compared to.
Measuring the HIV reservoirs: new and improved methods Sarah Palmer Westmead Millennium Institute for Medical Research University of Sydney.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Twice Weekly Peg-IFN-alpha-2a with Ribavirin Improves Early Viral Kinetics over Standard Therapy Among HIV/HCV Co-Infected African American Patients Alison.
Functional cure after long term HAART initiated during early HIV infection - a case study. van Lunzen J. 1,2, Schulze zur Wiesch J. 1,2, Schumacher U.
Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.
HIV-1 infection decreases CD127 and PD1 expression on duodenal CD8+T cells Liliana Belmonte, PhD Academia Nacional de Medicina Buenos Aires, Argentina.
Lessons Learned from Transient Remission Cases: Clues to Biomarkers of HIV Rebound Katherine Luzuriaga, MD University of Massachusetts.
HIV: Science, Sex and Society. Lecture 2. Strategies for the cure of HIV-1. Mario Stevenson, Ph.D Department of Medicine.
Title Box. “Towards an HIV Cure”: Presentation Outline -Why do we need a cure? -Is a cure feasible and what type of cure can we reach? -Why does HAART.
HBV (chronic) HIV ~400 million chronically infected
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:
Immune reconstitution Anjie Zhen, PhD
2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.
The HIV virus. Objectives At the end of this session the participants will be able to: 1. Understand basic HIV structure 2. Describe the significance.
Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam,
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
Bone Marrow Transplantation: A Novel Treatment for HIV Seropositives
Prolonged HIV-1 Remission and Viral Rebound in an Individual Treated During Hyperacute Infection Timothy Henrich, Hiroyu Hatano, Alison Hill, Oliver Bacon,
Rapporteur Report – Track A Basic and Translational Sciences
Emory University School of Medicine Department of Medicine
State of HIV Cure Research
No Evidence Of Ongoing Replication In Tissue Compartments During cART
A HIGHER FRACTION OF DRUG RESISTANT PROVIRUSES EXPRESS UNSPLICED HIV RNA DURING ART COMPARED TO THE ARCHIVAL WILD-TYPE PROVIRUSES THAT COMPRISE THE HIV-1.
HIV Cure: Current Status and Future Perspectives
Conflict of Interest No conflicts of interest to declare.
Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”.
Feedback meeting September 2017
The block-and-lock approach
Monique Nijhuis University Medical Center Utrecht, the Netherlands
Li Huang Duke University, North Carolina, USA
Volume 12, Issue 1, Pages (July 2005)
What Integration Sites Tell Us about HIV Persistence
Aim What happens when a bacteria or virus mutates?
Presentation transcript:

Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard A. Lempicki, and H. Clifford Lane. Cryptic transcription of HIV-RNA species from “defective” proviruses: A novel pathway for persistent immune activation in patients with HIV-1 infection and mechanism for persistent seropositivity despite “undetectable” levels of virus NIAID, NIH, DHHS; Leidos Biomedical Research, Inc.; Pacific Biosciences

The authors declare no competing financial interests. Conflict of interest

Previous observations Despite years of successful therapy (defined as HIV-RNA levels <50 copies/ml), the majority of HIV- infected patients exhibit persistent seropositivity to HIV-1 and evidence of chronic immune activation. While plasma HIV-RNA levels are often referred to as “undetectable”, cell-associated proviral DNA can still be detected in circulating PBMCs. Much of this proviral DNA has been characterized as “defective”. We have recently reported that such “defective” proviral DNA is capable of transcribing RNA. (Imamichi et al., AIDS, 2014;28:1091)

Interestingly, in the setting of bone marrow transplantation, a loss of seropositivity has been reported in association with a loss of proviral DNA. (continued) Previous observations - Hϋtter et al., NEJM, 2009;360:692 - Henrich et al., JID, 2013;207: A patient treated at the NIH Clinical Center (unpublished data)

Purpose Determine whether or not the peripheral blood pool of proviral DNA is capable of being transcribed and translated into viral proteins even if unable to encode an intact virus.

Study design

Study participants Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Yrs. since 1 st tested Pos HIV-RNA (copies/ml) <50 <40 <50 <40 CD4 + (cells/µl) , ,142 1,372 1,227 Yrs. of HIV-RNA < ART regimen 3TC+d4T+RT V FTC+TDF+EFV 3TC+d4T+RT V 3TC+AZT+NFV FTC+TDF+RTV +ATV FTC+TDF+NVP ABC+3TC+EFV Pt 8 n.a. >500,

High prevalence of truncated “defective” proviruses in a patient with prolonged viral suppression

Clonal expansion of truncated “defective” proviruses

Frequencies of proviruses with different lengths

The truncated “defective” proviruses are associated with novel RNA transcripts

H9 cells infected with HIV MN are capable of expressing HIV-1 proteins in the absence of intact proviruses

Summary Utilizing an LTR to LTR “full-length” PCR, we identified a high prevalence of “defective” proviruses in patients with prolonged viral suppression. - Are associated with RNA transcription - Are capable of encoding viral proteins in the absence of an intact virus - Could be found in cells undergoing clonal expansions and thus were associated with long-term persistence - Contain large internal deletions These proviruses:

Summary (continued) These “defective” proviruses: - Are incapable of producing intact viruses - Can still inflict harm by producing foreign proteins or by recombining to form intact viruses These results may help to explain: - The persistent seropositivity in most patients with controlled HIV-1 infection - The sero-reversions seen in a limited number of patients following transplantation Strategies directed toward “curing” HIV-1 need to include approaches designed to eliminate cells harboring such proviruses - The persistent immune activation in patients with HIV-RNA levels <50 copies/ml - The delayed time to rebound in the Mississippi baby

Acknowledgements Pacific Biosciences Yan Guo Lori Dodd Colleen Ludka Michael Brown Ellen Paxinos NIAID, NIH Cliff Lane Catherine A. Rehm Colleen Hadigan Leidos Biomedical Research Richard Lempicki Da Wei Huang Joseph Adelsberger Tomozumi Imamichi Robin Dewar Clinical and Laboratory staff at the NIAID/CCMD clinic and Leidos Biomedical Research The study participants Dun Liang